» Articles » PMID: 28769979

Safety and Effectiveness of Endoscopist-Directed Nurse-Administered Sedation During Gastric Endoscopic Submucosal Dissection

Overview
Publisher Wiley
Specialty Gastroenterology
Date 2017 Aug 4
PMID 28769979
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Endoscopic submucosal dissection (ESD) is routinely performed in treating gastric neoplasia and requires long-term higher levels of sedation. Endoscopist-directed nurse-administered sedation (EDNAS) has not been well studied in ESD. This study aimed to evaluate the safety and effectiveness of EDNAS for ESD.

Methods: Patients treated with ESD for gastric tumors between 2013 and 2015 were retrospectively collected. Patients were divided into a midazolam-treated group (M group) and a midazolam plus propofol-treated group (MP group). Clinical outcome, safety, effectiveness, adverse events of ESD, and adverse events of sedation were analyzed.

Results: Of 209 collected patients, 83 were in the M group and 126 were in the MP group. Of all patients, 67 patients had the circulatory adverse event during the ESD procedure. Sedation method was the only significant risk factor (M versus MP: 2.17 (1.14-4.15), = 0.019). In analysis of MP subgroups, 47 patients suffered an adverse event from sedation, and current smoking was the only significant association factor for adverse event (0.15 (0.03-0.68), = 0.014).

Conclusions: In performing ESD, the effect of sedation is reduced in smoking patients. EDNAS may be acceptable for ESD under careful monitoring of vital sign and oxygen saturation.

Citing Articles

Risk factors associated with surveillance loss after endoscopic submucosal dissection in patients with gastric neoplasm.

Lee M, Kim K, Lee Y, Park B, Lee S, Jeon H Ann Transl Med. 2021; 9(14):1127.

PMID: 34430568 PMC: 8350673. DOI: 10.21037/atm-21-891.


Safety and Efficacy of Nonanesthesiologist-Administrated Propofol during Endoscopic Submucosal Dissection of Gastric Epithelial Tumors.

Abe K, Tominaga K, Kanamori A, Suzuki T, Kino H, Nakano M Gastroenterol Res Pract. 2019; 2019:5937426.

PMID: 30755768 PMC: 6348925. DOI: 10.1155/2019/5937426.

References
1.
. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002; 96(4):1004-17. DOI: 10.1097/00000542-200204000-00031. View

2.
Lee H, Cheoi K, Chung H, Park J, Shin S, Lee S . Clinical features and predictive factors of coagulation syndrome after endoscopic submucosal dissection for early gastric neoplasm. Gastric Cancer. 2011; 15(1):83-90. DOI: 10.1007/s10120-011-0073-x. View

3.
Rex D, Deenadayalu V, Eid E, Imperiale T, Walker J, Sandhu K . Endoscopist-directed administration of propofol: a worldwide safety experience. Gastroenterology. 2009; 137(4):1229-37. DOI: 10.1053/j.gastro.2009.06.042. View

4.
Larijani G, Gratz I, Afshar M, Jacobi A . Clinical pharmacology of propofol: an intravenous anesthetic agent. DICP. 1989; 23(10):743-9. DOI: 10.1177/106002808902301001. View

5.
Ooi M, Thomson A . Morbidity and mortality of endoscopist-directed nurse-administered propofol sedation (EDNAPS) in a tertiary referral center. Endosc Int Open. 2015; 3(5):E393-7. PMC: 4612235. DOI: 10.1055/s-0034-1392511. View